Trial
NCT03206463
Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
—
Condition
Delta-9-Tetrahydroncannabinol
Intervention
4 mg Delta-9-THC
Why stopped
Feasibility pilot was completed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-31